Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells

• Published in: Medical oncology (Northwood, London, England) London, England), 2023-08, Vol.40 (9), p.263-263, Article 263
• Main Authors: Hedayat, Mohaddeseh, Khezri, Mohammad Rafi, Jafari, Reza, Malekinejad, Hassan, Majidi Zolbanin, Naime
• Format: Article
• Language: English
• Subjects: Apoptosis; bcl-2-Associated X Protein - metabolism; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Caspase 3 - metabolism; Celecoxib - pharmacology; Cell Line, Tumor; Female; Gene expression; Hematology; Humans; Internal Medicine; Medicine; Medicine & Public Health; Metastasis; Oncology; Original Paper; Paclitaxel - pharmacology; Pathology; Proto-Oncogene Proteins c-bcl-2 - genetics; Proto-Oncogene Proteins c-bcl-2 - metabolism; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - metabolism
• ISSN: 1559-131X; 1357-0560; 1559-131X
• DOI: 10.1007/s12032-023-02119-1

Although triple-negative breast cancer accounts for less than one-fifth of breast cancers, it has a higher rate of metastasis and mortality. This study investigated the effects of combination treatment with paclitaxel and celecoxib on the expression of genes involved in the apoptosis of triple-negative metastatic breast cancer cells. MDA-MB-231 cells were cultured and then treated with certain concentrations of celecoxib (CLX), paclitaxel (PTX), and combination of them for 24 and 48 h. Cell viability was assessed by the MTT method. The real-time PCR method was utilized to assess the expression level of the genes involved in apoptosis. Western blotting was used for evaluating protein expression. IC 50 values for CLX and PTX were 73.95 μM and 3.15 μM, respectively. The results demonstrated that PTX, CLX, and PTX + CLX significantly ( p